Abstract

Following the publication of this paper, the authors alerted the Editorial Office to the fact that a reader had informed them that miR‑152 overexpression did not affect cell apoptosis and cell cycle. The authors subsequently confirmed that they were unable to obtain consistent results from these experiments.Furthermore, an independent investigation of this paper revealed that the cell apoptotic data shown in Fig.2D were strikingly similar to those that had appeared in an article published previously with different authors, although one of the institutions was held in common. The authors have requested that the above article be retracted from the publication, and the Editor agrees with this course of action. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Molecular Medicine 42: 643‑650, 2018; DOI: 10.3892/ijmm.2018.3636].

Highlights

  • Following the publication of this paper, the authors alerted the Editorial Office to the fact that a reader had informed them that miR‐152 overexpression did not affect cell apoptosis and cell cycle

  • An independent investigation of this paper revealed that the cell apoptotic data shown in Fig. 2D were strikingly similar to those that had appeared in an article published previously with different authors, one of the institutions was held in common

  • The Editor apologizes to the readership for any inconvenience caused

Read more

Summary

Introduction

MiR‐152 inhibits rheumatoid arthritis synovial fibroblast proliferation and induces apoptosis by targeting ADAM10

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.